Faraz Khursheed, MD
Neurology · Hollywood, FLNPI 1376705681
Payments from drug & device makers
Across 485 payments — averaging $92.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$33K
- Abbott$4K
- Biotronik NRO, Inc.$4K
- Collegium Pharmaceutical, Inc.$552
- AbbVie$535
- Zyla Life Sciences, Inc.$439
- plus $2K from 30 others
What the payments were for
- Food & beverage$11,810100%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 3 | $33,105 |
| Abbott | 198 | $4,448 |
| Biotronik NRO, Inc. | 64 | $3,988 |
| Collegium Pharmaceutical, Inc. | 32 | $552 |
| AbbVie(2 entities) | 27 | $535 |
| Zyla Life Sciences, Inc. | 59 | $439 |
| Pfizer | 20 | $401 |
| Scilex Pharmaceuticals Inc. | 21 | $372 |
| Redhill Biopharma Inc. | 8 | $135 |
| Boston Scientific | 6 | $134 |
| Medtronic(2 entities) | 7 | $129 |
| Biodelivery Sciences International, Inc. | 6 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| Nevro Corp. | 3 | $50 |
| AstraZeneca | 3 | $44 |
| Globus Medical | 1 | $40 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Nalu Medical, Inc. | 1 | $26 |
| Hyperfine Operations, Inc. | 1 | $26 |
| Amgen | 2 | $25 |
| GRT US Holding, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Assertio Therapeutics, Inc. | 1 | $22 |
| Masimo Corporation | 1 | $22 |
| DJO, LLC | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $21 |
| Pernix Therapeutics Holdings, Inc. | 1 | $20 |
| Shionogi Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Orexo US, Inc. | 1 | $16 |
| Forte Bio-pharma LLC | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
| Sentynl Therapeutics, Inc. | 1 | $13 |
| Vertiflex, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prospera$1,483
- Proclaim Family of SCS IPGs$141
- Proclaim IPG$133
How this compares
$44,968 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 38 | $24,127 |
| UbrelvyUbrogepant | 14 | $23,270 |
| BotoxOnabotulinumtoxina | 11 | $13,791 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 329 | $12,385 |
| Zolmitriptan | 13 | $11,736 |
| Sumatriptan Succinate | 13 | $11,053 |
| MovantikNaloxegol Oxalate | 15 | $6,092 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 164 | $4,114 |
| Gabapentin | 163 | $1,884 |
| Lubiprostone | 17 | $1,580 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,396 |
| Amitriptyline Hcl | 114 | $1,176 |
| Tizanidine Hcl | 94 | $884 |
| Morphine Sulfate ErMorphine Sulfate | 48 | $829 |
| Pregabalin | 23 | $759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox | $535 | $37,06125 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $552 | $24,12738 claims |
| Redhill Biopharma Inc.Movantik | $135 | $6,09215 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $12 | $1,39611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.
Other neurology in Hollywood
- Harvey SchwartzHollywood$5.9M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.